Myomo, Inc. Announces the Launch of Myomo Academy at AOPA National Assembly
Myomo, Inc. (NYSE American: MYO) has launched the Myomo Academy, a comprehensive learning management system for professionals in Orthotics & Prosthetics (O&P) and Rehabilitation.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
The Myomo Academy is being launched during the 2024 AOPA (American Orthotic and Prosthetic Association) National Assembly, which is underway in
The Myomo Academy is designed to provide ongoing education, featuring a wide range of courses from introductory to advanced levels. With a structured curriculum tailored to support Centers of Excellence and therapy training, these courses will offer easy access to clinically relevant content and ensure that clinicians remain at the forefront of upper-extremity myoelectric orthosis technology.
“We are thrilled to introduce the Myomo Academy as a central resource for enhancing outcomes and education in O&P and rehabilitation, and we’re excited to help more clinicians advance their knowledge of myoelectric orthotics,” said Kathy Sawyers, PT, ATP, Sr. Director of Clinical Outcomes.
“By leveraging our expertise, we are committed to delivering exceptional educational content that is unique and not readily available elsewhere, helping clinicians provide the best care for their patients,” said Paul R. Gudonis, Chairman and CEO of Myomo, Inc.
About Myomo, Inc.
Myomo, Inc. is a wearable medical robotics company that offers improved arm and hand function for those suffering from neurological disorders and upper limb paralysis. Myomo develops and markets the MyoPro product line. MyoPro is a powered upper limb orthosis designed to support the arm and restore function to the weakened or paralyzed arms of patients suffering from CVA stroke, brachial plexus injury, traumatic brain or spinal cord injury or other neuromuscular disease or injury. It is currently the only marketed device in the
Myomo is headquartered in
View source version on businesswire.com: https://www.businesswire.com/news/home/20240912701943/en/
Joseph Chicoskie
Director of Marketing
Myomo, Inc.
Email: joseph.chicoskie@myomo.com
Phone: 833-927-3671
Website: www.myomo.com
Source: Myomo, Inc.